Sheela Sitaraman

806 total citations
33 papers, 447 citations indexed

About

Sheela Sitaraman is a scholar working on Physiology, Rheumatology and Molecular Biology. According to data from OpenAlex, Sheela Sitaraman has authored 33 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Physiology, 10 papers in Rheumatology and 9 papers in Molecular Biology. Recurrent topics in Sheela Sitaraman's work include Lysosomal Storage Disorders Research (21 papers), Glycogen Storage Diseases and Myoclonus (9 papers) and Trypanosoma species research and implications (6 papers). Sheela Sitaraman is often cited by papers focused on Lysosomal Storage Disorders Research (21 papers), Glycogen Storage Diseases and Myoclonus (9 papers) and Trypanosoma species research and implications (6 papers). Sheela Sitaraman collaborates with scholars based in United States, Australia and United Kingdom. Sheela Sitaraman's co-authors include David J. Lockhart, Pol Boudes, Richie Khanna, Kenneth J. Valenzano, Kathy Nicholls, Rebecca Soska, Jeff Castelli, Elfrida R. Benjamin, Nastry Brignol and Dominique P. Germain and has published in prestigious journals such as PLoS ONE, Neurology and Journal of Pharmaceutical Sciences.

In The Last Decade

Sheela Sitaraman

26 papers receiving 433 citations

Peers

Countries citing papers authored by Sheela Sitaraman

Since Specialization

Citations

This map shows the geographic impact of Sheela Sitaraman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheela Sitaraman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheela Sitaraman more than expected).

Fields of papers citing papers by Sheela Sitaraman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheela Sitaraman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheela Sitaraman. The network helps show where Sheela Sitaraman may publish in the future.

Co-authorship network of co-authors of Sheela Sitaraman

This figure shows the co-authorship network connecting the top 25 collaborators of Sheela Sitaraman. A scholar is included among the top collaborators of Sheela Sitaraman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheela Sitaraman. Sheela Sitaraman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk assessment and management strategy of two new NDSRIs in a pharmaceutical drug product for the treatment of a rare disease: From prediction to control 2025 ·Journal of Pharmaceutical Sciences ·Partha P. Mukherjee, Xin Yao, Sheela Sitaraman, Jeff Castelli, (unknown), Sithara Ramdas	1
2	Analytical Method Development Strategy for Controlling Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for Treatment of a Rare Disease 2025 ·Chromatographia ·Partha P. Mukherjee, Xin Yao, Nastry Brignol, Moses V. Chao, Steven Tuske, M. Osman Sheikh, (unknown), Sheela Sitaraman, Jill M. Weimer, Sithara Ramdas	1
3	AI-Driven Diagnostics and Imaging: Transforming Early Detection and Precision in Healthcare 2024 ·International Journal of Scientific Research in Computer Science Engineering and Information Technology ·Sheela Sitaraman	0
4	Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification 2023 ·Biomolecules ·(unknown), Simon Shohet, Jeff Castelli, Sheela Sitaraman, (unknown), Jill M. Weimer, Brian W. Fox, Tobias Willer, Steve Tuske, Louise Crathorne, (unknown)	15
5	Long-term Follow-up of Cipaglucosidase Alfa/Miglustat in Ambulatory Patients with Pompe Disease: An Open-label Phase I/II Study (ATB200-02) (S48.007) 2023 ·Neurology ·Tahseen Mozaffar, Benedikt Schoser, Priya S. Kishnani, Drago Bratkovic, Paula R. Clemens, (unknown), Xue Ming, Mark Roberts, Kumaraswamy Sivakumar, Ans van der Ploeg, Mitchell Goldman, (unknown), Fred Holdbrook, (unknown), Sheela Sitaraman, Yasmine Wasfi, Barry J. Byrne	1
6	Indirect treatment comparison of three enzyme replacement treatments for late-onset Pompe disease: A network meta-analysis with patient-level and aggregate data 2023 ·Molecular Genetics and Metabolism ·Jeff Castelli, Shuai Fu, Noemi Hummel, Tahseen Mozaffar, Brian A. Fox, (unknown), (unknown), Sheela Sitaraman, Simon Shohet	1
7	eP157: Efficacy and safety of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study 2022 ·Genetics in Medicine ·Priya S. Kishnani, Drago Bratkovic, Barry J. Byrne, Jordi Díaz‐Manera, Pascal Laforêt, Tahseen Mozaffar, Ans van der Ploeg, Mark Roberts, António Toscano, Hai Jiang, Sheela Sitaraman, Mitchell H. Goldman, Jeff Castelli, Benedikt Schoser	0
8	Use of the patient-reported outcomes measurement information system (PROMIS®) to assess late-onset Pompe disease severity 2020 ·Journal of Patient-Reported Outcomes ·(unknown), Priya S. Kishnani, (unknown), (unknown), Sheela Sitaraman, (unknown), (unknown), Stephanie Austin, Margi E. Goldstein, Andrew E. Mulberg	7
9	Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders 2019 ·Orphanet Journal of Rare Diseases ·Andrew E. Mulberg, Christina Bucci‐Rechtweg, Joseph Giuliano, David Jacoby, Franklin K. Johnson, Qing Liu, Deborah Marsden, (unknown), Robert M. Nelson, Nita Patel, Klaus Romero, Vikram Sinha, Sheela Sitaraman, (unknown), (unknown)	37
10	First-in-human study of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in patients with Pompe disease: preliminary functional assessment results from the ATB200-02 trial 2019 ·Molecular Genetics and Metabolism ·Priya S. Kishnani, Benedikt Schoser, Drago Bratkovic, Barry J. Byrne, Paula R. Clemens, Özlem Göker-Alpan, Xue Ming, Mark Roberts, Peter Schwenkreis, Kumaraswamy Sivakumar, Ans T. van der Ploeg, (unknown), Sheela Sitaraman, Jay Barth, Hjalmar Lagast, Tahseen Mozaffar	5
11	Joint involvement in children with celiac disease 2017 ·Indian Pediatrics ·Kapil Garg, Priyanka Agarwal, Raj K. Gupta, Sheela Sitaraman	12
12	Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase 2015 ·PLoS ONE ·David G. Warnock, Daniel G. Bichet, Myrl Holida, Özlem Göker-Alpan, Kathy Nicholls, Mark Thomas, François Eyskens, Suma P. Shankar, (unknown), Sheela Sitaraman, Richie Khanna, John J. Flanagan, Brandon A. Wustman, Jay Barth, Carrolee Barlow, Kenneth J. Valenzano, David J. Lockhart, Pol Boudes, Franklin K. Johnson	49
13	Phase 3 study of migalastat HCl for Fabry disease: Stage 1 results 2013 ·Molecular Genetics and Metabolism ·Kathy Nicholls, Dominique P. Germain, Claudio Feliciani, Suma P. Shankar, Fatih Süheyl Ezgü, Salim Janmohamed, (unknown), (unknown), (unknown), Sheela Sitaraman, Pol Boudes	4
14	Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients 2013 ·PLoS ONE ·(unknown), Nastry Brignol, Hui‐Hwa Chang, Richie Khanna, Rebecca Soska, Maria Fuller, Sheela Sitaraman, Dominique P. Germain, Roberto Giugliani, Derralynn Hughes, Atul Mehta, Kathy Nicholls, Pol Boudes, David J. Lockhart, Kenneth J. Valenzano, Elfrida R. Benjamin	35
15	Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies 2012 ·Orphanet Journal of Rare Diseases ·Dominique P. Germain, Roberto Giugliani, Derralynn Hughes, Atul Mehta, Kathy Nicholls, Laura Barisoni, (unknown), (unknown), Jeff Castelli, Sheela Sitaraman, David J. Lockhart, Pol Boudes	77
16	T.P.45 An ongoing phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alpha glucosidase in subjects with Pompe disease – Preliminary results 2012 ·Neuromuscular Disorders ·Priya S. Kishnani, Mark A. Tarnopolsky, K Sivakumar, Barry J. Byrne, Özlem Göker-Alpan, (unknown), Muhammad Pervaiz, Majed Dasouki, T. Levine, Mark Roberts, Franklin K. Johnson, Sheela Sitaraman, Rajiv Khanna, John J. Flanagan, Eric R. Sjoberg, Kenneth J. Valenzano, David J. Lockhart, Pol Boudes	2
17	Pharmacokinetics and muscle distribution of AT2220, a pharmacological chaperone of acid-glucosidase, in healthy volunteers 2011 ·Molecular Genetics and Metabolism ·(unknown), Pol Boudes, (unknown), Sheela Sitaraman, (unknown), (unknown), George R. Lankas, R Stoltz, Jane Royalty, Douglas S. Greene	1
18	The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease 2009 ·Molecular Therapy ·Richie Khanna, Rebecca Soska, Yi Lun, Jessie Feng, Michelle Frascella, Brandy Young, Nastry Brignol, Lee Pellegrino, Sheela Sitaraman, Robert J. Desnick, Elfrida R. Benjamin, David J. Lockhart, Kenneth J. Valenzano	107
19	Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice 2000 ·Journal of Neuroimmunology ·Sheela Sitaraman, Dennis W. Metzger, (unknown), Anthony J. Infante, Katherine A. Wall	16
20	Accidents in infancy and childhood. 1985 ·PubMed ·Sheela Sitaraman, Usha Sharma, Shekhar Saxena, (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact